stat3 in 8

JH-I-25 is an IRAK1 kinase inhibitor.

"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."

WCY-8-67 TFA is an orally bioavailable selective USP5 inhibitor with an IC₅₀ of 1.33 μM. It induces apoptosis in vitro and inhibits the JAK/STAT3 and PI3K/AKT signaling pathways. WCY-8-67 TFA suppresses the proliferation of AE-positive acute myeloid leukemia (AML) cells, induces G1 phase cell cycle arrest, and promotes cell differentiation. It shows significant anti-leukemic activity in mouse in vivo experiments and can be used in AML research.

Icaritin (Standard) is a reference standard for research and analysis in studies involving Icaritin. Icaritin (Anhydroicaritin) has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase arrest and apoptosis, inhibit ENKL cell proliferation. Icaritin has anti-multiple myeloma activity, mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. Icaritin at low concentration (4 or 8 μMol/L) can promote rat chondrocyte proliferation and inhibit cell apoptosis, while the effect of Icaritin on rat chondrocyte at high concentration was reversed.